Research Progress in Brachytherapy for Cervical Cancer

doi:10.12280/gjfckx.20210574

Abstract

Abstract:

Cervical cancer is the most common malignant tumor of female reproductive tract in China, which seriously threatens women′s health. Brachytherapy is an essential component of the treatment of locally advanced cervical cancers. It enables the dose to the tumor to be boosted whilst allowing relative sparing of the normal tissues. In recent years, three-dimensional brachytherapy, interstitial implantation brachytherapy and radioactive seed implantation brachytherapy have developed rapidly. These technologies have improved the treatment effect of cervical cancer and reduced complications. The three factors are interrelated. For eccentric tumor, intracavitary brachytherapy has incomplete target coverage and poor dose distribution conformation, while interstitial implantation brachytherapy can make up for the deficiency of intracavitary brachytherapy. Radioactive seed implantation brachytherapy has the characteristics of low trauma and high safety, providing more possibilities for patients with recurrent cervical cancer. Therefore, individualized treatment plan should be formulated according to the characteristics of the patient′s condition in clinical practice.

Key words: Uterine cervical neoplasms, Brachytherapy, Iodine radioisotopes, Radioactivity, 3D printing, Tomography

JIN Ge, LI Kui-xiu, GUO Yun-feng, GAO Yang-yang. Research Progress in Brachytherapy for Cervical Cancer[J]. Journal of International Obstetrics and Gynecology, 2022, 49(2): 202-206.

References 28

[1]	Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6):394-424. doi: 10.3322/caac.21492. doi: 10.3322/caac.21492
[2]	Small W Jr, Bacon MA, Bajaj A, et al. Cervical cancer: A global health crisis[J]. Cancer, 2017, 123(13):2404-2412. doi: 10.1002/cncr.30667. doi: 10.1002/cncr.30667
[3]	Ginsburg O, Bray F, Coleman MP, et al. The global burden of women′s cancers: a grand challenge in global health[J]. Lancet, 2017, 389(10071):847-860. doi: 10.1016/S0140-6736(16)31392-7. doi: S0140-6736(16)31392-7 pmid: 27814965
[4]	Mayadev J, Viswanathan A, Liu Y, et al. American Brachytherapy Task Group Report: A pooled analysis of clinical outcomes for high-dose-rate brachytherapy for cervical cancer[J]. Brachytherapy, 2017, 16(1):22-43. doi: 10.1016/j.brachy.2016.03.008. doi: S1538-4721(16)30015-0 pmid: 28109631
[5]	Sturdza A, Pötter R, Fokdal LU, et al. Image guided brachytherapy in locally advanced cervical cancer: Improved pelvic control and survival in RetroEMBRACE, a multicenter cohort study[J]. Radiother Oncol, 2016, 120(3):428-433. doi: 10.1016/j.radonc.2016.03.011. doi: S0167-8140(16)31018-0 pmid: 27134181
[6]	丁文婷, 邢舒, 何丽, 等. 三维近距离放射治疗Ⅱb-Ⅳa期宫颈癌效果及预后观察[J]. 临床误诊误治, 2021, 34(1):92-97. doi: 10.3969/j.issn.1002-3429.2021.01.020. doi: 10.3969/j.issn.1002-3429.2021.01.020
[7]	Derks K, Steenhuijsen J, van den Berg HA, et al. Impact of brachytherapy technique (2D versus 3D) on outcome following radiotherapy of cervical cancer[J]. J Contemp Brachytherapy, 2018, 10(1):17-25. doi: 10.5114/jcb.2018.73955. doi: 10.5114/jcb.2018.73955
[8]	Pötter R, Tanderup K, Schmid MP, et al. MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study[J]. Lancet Oncol, 2021, 22(4):538-547. doi: 10.1016/S1470-2045(20)30753-1. doi: 10.1016/S1470-2045(20)30753-1
[9]	Haie-Meder C, Pötter R, Van Limbergen E, et al. Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (I): concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV[J]. Radiother Oncol, 2005, 74(3):235-245. doi: 10.1016/j.radonc.2004.12.015. doi: 10.1016/j.radonc.2004.12.015 pmid: 15763303
[10]	Schmid MP, Kirisits C, Nesvacil N, et al. Local recurrences in cervical cancer patients in the setting of image-guided brachytherapy: a comparison of spatial dose distribution within a matched-pair analysis[J]. Radiother Oncol, 2011, 100(3):468-472. doi: 10.1016/j.radonc.2011.08.014. doi: 10.1016/j.radonc.2011.08.014
[11]	Dimopoulos JC, Lang S, Kirisits C, et al. Dose-volume histogram parameters and local tumor control in magnetic resonance image-guided cervical cancer brachytherapy[J]. Int J Radiat Oncol Biol Phys, 2009, 75(1):56-63. doi: 10.1016/j.ijrobp.2008.10.033. doi: 10.1016/j.ijrobp.2008.10.033
[12]	Mazeron R, Castelnau-Marchand P, Escande A, et al. Tumor dose-volume response in image-guided adaptive brachytherapy for cervical cancer: A meta-regression analysis[J]. Brachytherapy, 2016, 15(5):537-542. doi: 10.1016/j.brachy.2016.05.009. doi: 10.1016/j.brachy.2016.05.009 pmid: 27371991
[13]	Fokdal L, Pötter R, Kirchheiner K, et al. Physician assessed and patient reported urinary morbidity after radio-chemotherapy and image guided adaptive brachytherapy for locally advanced cervical cancer[J]. Radiother Oncol, 2018, 127(3):423-430. doi: 10.1016/j.radonc.2018.05.002. doi: S0167-8140(18)30242-1 pmid: 29784450
[14]	Tanderup K, Lindegaard JC, Kirisits C, et al. Image Guided Adaptive Brachytherapy in cervix cancer: A new paradigm changing clinical practice and outcome[J]. Radiother Oncol, 2016, 120(3):365-369. doi: 10.1016/j.radonc.2016.08.007. doi: S0167-8140(16)31248-8 pmid: 27555228
[15]	Tharavichitkul E, Chakrabandhu S, Klunklin P, et al. Intermediate-term results of trans-abdominal ultrasound (TAUS)-guided brachytherapy in cervical cancer[J]. Gynecol Oncol, 2018, 148(3):468-473. doi: 10.1016/j.ygyno.2018.01.015. doi: S0090-8258(18)30047-7 pmid: 29398070
[16]	Théodore C, Levaillant JM, Capmas P, et al. MRI and Ultrasound Fusion Imaging for Cervical Cancer[J]. Anticancer Res, 2017, 37(9):5079-5085. doi: 10.21873/anticanres.11925. doi: 10.21873/anticanres.11925 pmid: 28870937
[17]	Lin X, Wang JP, Liu ZS, et al. Dose distribution of brachytherapy for locally advanced (stage IIB) cervical cancer[J]. Brachytherapy, 2020, 19(1):66-72. doi: 10.1016/j.brachy.2019.10.004. doi: 10.1016/j.brachy.2019.10.004
[18]	Nag S, Erickson B, Thomadsen B, et al. The American Brachytherapy Society recommendations for high-dose-rate brachytherapy for carcinoma of the cervix[J]. Int J Radiat Oncol Biol Phys, 2000, 48(1):201-211. doi: 10.1016/s0360-3016(00)00497-1. doi: 10.1016/s0360-3016(00)00497-1
[19]	Murakami N, Kobayashi K, Kato T, et al. The role of interstitial brachytherapy in the management of primary radiation therapy for uterine cervical cancer[J]. J Contemp Brachytherapy, 2016, 8(5):391-398. doi: 10.5114/jcb.2016.62938. doi: 10.5114/jcb.2016.62938
[20]	Murakami N, Kato T, Miyamoto Y, et al. Salvage High-dose-rate Interstitial Brachytherapy for Pelvic Recurrent Cervical Carcinoma After Hysterectomy[J]. Anticancer Res, 2016, 36(5):2413-2421. pmid: 27127151
[21]	张永侠, 袁香坤, 苗珺珺, 等. 3D打印模板应用于局部晚期宫颈癌后装放疗的剂量学研究[J]. 中华放射医学与防护杂志, 2020, 40(7):519-523. doi: 10.3760/cma.j.issn.0254-5098.2020.07.005. doi: 10.3760/cma.j.issn.0254-5098.2020.07.005
[22]	Liu ZS, Guo J, Zhao YZ, et al. Salvage interstitial brachytherapy based on computed tomography for recurrent cervical cancer after radical hysterectomy and adjuvant radiation therapy: case presentations and introduction of the technique[J]. J Contemp Brachytherapy, 2016, 8(5):415-421. doi: 10.5114/jcb.2016.63192. doi: 10.5114/jcb.2016.63192
[23]	郭小青, 廖晓红, 何静, 等. 三维后装插植放疗治疗阴道残端复发肿瘤[J]. 江西医药, 2019, 54(6):583-585,592. doi: 10.3969/j.issn.1006-2238.2019.6.001. doi: 10.3969/j.issn.1006-2238.2019.6.001
[24]	王琢, 陈健, 王宏雨, 等. 组织间插植近距离治疗和腔内近距离治疗对局部晚期宫颈癌患者生存期和生存质量的影响[J]. 中国医学前沿杂志(电子版), 2019, 11(10):90-94. doi: 10.12037/YXQY.2019.10-20. doi: 10.12037/YXQY.2019.10-20
[25]	Han L, Li C, Wang J, et al. Iodine-125 radioactive seed tissue implantation as a remedy treatment for recurrent cervical cancer[J]. J Cancer Res Ther, 2016,12(Suppl):C176-C180. doi: 10.4103/0973-1482.200611. doi: 10.4103/0973-1482.200611
[26]	Qu A, Jiang P, Sun H, et al. Efficacy and dosimetry analysis of image-guided radioactive ¹²⁵I seed implantation as salvage treatment for pelvic recurrent cervical cancer after external beam radiotherapy[J]. J Gynecol Oncol, 2019, 30(1):e9. doi: 10.3802/jgo.2019.30.e9. doi: 10.3802/jgo.2019.30.e9
[27]	江萍, 郭福新, 姜玉良, 等. 3D打印非共面模板辅助CT引导¹²⁵I粒子植入治疗盆腔复发子宫颈癌的剂量学研究[J]. 中华放射医学与防护杂志, 2017, 37(7):490-494. doi: 10.3760/cma.j.issn.0254-5098.2017.07.003. doi: 10.3760/cma.j.issn.0254-5098.2017.07.003
[28]	Liu Y, Jiang P, Zhang H, et al. Safety and efficacy of 3D-printed templates assisted CT-guided radioactive iodine-125 seed implantation for the treatment of recurrent cervical carcinoma after external beam radiotherapy[J]. J Gynecol Oncol, 2021, 32(2):e15. doi: 10.3802/jgo.2021.32.e15. doi: 10.3802/jgo.2021.32.e15